Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanna Dodd

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Health Technology Assessment (Winchester, England)|December 22, 2025
A community-based rehabilitation package following hip fracture: FEMuR III a multi-centre RCT, economic and process evaluationNefyn H Williams, Monica Busse, Rachael Cooper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Gut|December 3, 2009
The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis familiesChristopher J Grocock, Vinciane Rebours, Myriam N Delhaye, et al.
The Journal of Rheumatology|January 17, 2019
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OsteoarthritisToby O Smith, Gillian A Hawker, David J Hunter, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Health Technology Assessment (Winchester, England)|December 22, 2025
A community-based rehabilitation package following hip fracture: FEMuR III a multi-centre RCT, economic and process evaluationNefyn H Williams, Monica Busse, Rachael Cooper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Gut|December 3, 2009
The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis familiesChristopher J Grocock, Vinciane Rebours, Myriam N Delhaye, et al.
The Journal of Rheumatology|January 17, 2019
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OsteoarthritisToby O Smith, Gillian A Hawker, David J Hunter, et al.
Pageof 9